NDV-01 (sustained-release gemcitabine-docetaxel)

Phase 3Withdrawn

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Bladder (Urothelial, Transitional Cell) Cancer

Conditions

Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent, Urologic Cancer

Trial Timeline

Jun 30, 2026 → Jun 30, 2028

NCT ID

NCT07342517

About NDV-01 (sustained-release gemcitabine-docetaxel)

NDV-01 (sustained-release gemcitabine-docetaxel) is a phase 3 stage product being developed by Relmada Therapeutics for Bladder (Urothelial, Transitional Cell) Cancer. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT07342517. Target conditions include Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Urothelial Carcinoma Bladder.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07342517	Phase 3	Withdrawn	Jun 30, 2026	Jun 30, 2028	Bladder (Urothelial, Transitional Cell) Cancer
NCT07464145	Phase 3	Recruiting	Jun 1, 2026	Sep 1, 2032	Bladder (Urothelial, Transitional Cell) Cancer
NCT07313891	Phase 3	Withdrawn	May 1, 2026	Nov 1, 2029	Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)

Competing Products

20 competing products in Bladder (Urothelial, Transitional Cell) Cancer

See all competitors

Product	Company	Stage	Hype Score
pegylated liposomal doxorubicin (PLD) + PD-1	CSPC Pharmaceutical Group Limited	Phase 2	51
EG-70 (phase 1) + EG-70 (phase 2)	enGene	Phase 1/2	33
mirabegron + solifenacin	Astellas Pharma	Approved	85
Trastuzumab deruxtecan	Daiichi Sankyo	Phase 2	52
Enfortumab vedotin	Astellas Pharma	Phase 1	33
Mirabegron + Placebo	Astellas Pharma	Approved	85
Solifenacin	Astellas Pharma	Approved	85
Mirabegron + Tolterodine + Placebo to Mirabegron + Placebo to Tolterodine	Astellas Pharma	Phase 3	77
solifenacin succinate	Astellas Pharma	Phase 3	77
Solifenacin	Astellas Pharma	Pre-clinical	23
Betanis	Astellas Pharma	Pre-clinical	23
Solifenacin	Astellas Pharma	Approved	85
Solifenacin	Astellas Pharma	Phase 2	52
Mirabegron + Tolterodine ER	Astellas Pharma	Approved	85
mirabegron + solifenacin + darifenacin + imidafenacin + tolterodine + oxybutynin + trospium + fesoterodine + propiverine	Astellas Pharma	Pre-clinical	23
Enfortumab vedotin + Pembrolizumab	Astellas Pharma	Phase 2	52
MK-3475 + ASG-22CE	Astellas Pharma	Phase 2	52
Enfortumab Vedotin + Pembrolizumab	Astellas Pharma	Phase 2	52
Alpha blocker + placebo + solifenacin	Astellas Pharma	Approved	85
warfarin + YM178	Astellas Pharma	Phase 1	33

Other Products from Relmada Therapeutics

REL-1017 + PlaceboPhase 3

NDV-01 (sustained-release gemcitabine-docetaxel)Phase 3

REL-1017Phase 3